NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company that discovers, develops and commercializes treatments for neurological, psychiatric, endocrine and immunological disorders. Its U.S.-approved products include INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington’s disease, and CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia. In collaboration with AbbVie, it has products for endometriosis and uterine fibroids. INGREZZA is marketed in Japan and select Asian markets by Tanabe Pharma under the DYSVAL and REMLEAS brands. Neurocrine sells INGREZZA in the U.S. through a limited specialty network and CRENESSITY through a single specialty pharmacy provider. It also develops a pipeline of drug candidates across its core therapeutic areas, including psychiatry and neurology programs. The company relies on third-party manufacturers to produce its products and candidates. Neurocrine Biosciences is headquartered in San Diego, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Morgan Stanley kept Neurocrine Biosciences at Equal-Weight, raising its price target to $191 from $185, implying a 12.8% upside from the Nov 12 close of $169.40. Recent analyst price targets for the company range from $185 to $224.
Neurocrine Biosciences reported Q3 record sales of $1.1B, up 40% YoY, with INGREZZA, CRENESSITY, and VYKAT XR driving growth. INGREZZA sales hit $801M, CRENESSITY surpassed $200M, and VYKAT XR reached $107M. The company raised full-year INGREZZA guidance to $2.9B-$2.925B and highlighted pipeline catalysts for 2027.
Guggenheim reaffirmed its Buy rating for Neurocrine Biosciences and increased its price target to $224 from $207, suggesting a 35.9% upside from the Nov 3 close of $164.85. Recent analyst price targets for the company range from $185 to $220.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning NBIX (NEUROCRINE BIOSCIENCES INC). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent NBIX coverage spans financial news, earnings and insider activity.
In the last 30 days, NBIX insiders filed 12 SEC Form 4 transactions — no purchases and 12 sales ($2.3M). The most active reporter was MORROW GEORGE J with 12 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The note is a modest bullish tilt via a higher price target, but it is not a new fundamental catalyst beyond analyst framing.
Neutral impact as the information is a repeat of already‑public results; no fresh catalyst.
Analyst upgrade suggests higher valuation.
Insider sale suggests potential downside pressure on NBIX.
Strong top‑line growth and solid product sales outlook support further upside.
AlphAI scores every news story that mentions NBIX with an AI model for sentiment and relevance, and aggregates insider trades from NEUROCRINE BIOSCIENCES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Morgan Stanley kept Neurocrine Biosciences at Equal-Weight, raising its price target to $191 from $185, implying a 12.8% upside from the Nov 12 close of $169.40. Recent analyst price targets for the company range from $185 to $224.
Neurocrine Biosciences reported Q3 record sales of $1.1B, up 40% YoY, with INGREZZA, CRENESSITY, and VYKAT XR driving growth. INGREZZA sales hit $801M, CRENESSITY surpassed $200M, and VYKAT XR reached $107M. The company raised full-year INGREZZA guidance to $2.9B-$2.925B and highlighted pipeline catalysts for 2027.
Guggenheim reaffirmed its Buy rating for Neurocrine Biosciences and increased its price target to $224 from $207, suggesting a 35.9% upside from the Nov 3 close of $164.85. Recent analyst price targets for the company range from $185 to $220.
MORROW GEORGE J sold 15,000 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at an average of $155.73 ($144.98–$168.53, $2.34M total) across 12 trades over 2026-10-30 to 2026-11-03 under a Rule 10b5-1 trading plan.
Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.
RBC Capital raised its price target for Neurocrine Biosciences to $190 from $187, implying a 30.7% upside from the Nov 2 close. The firm maintained an Outperform rating. Recent analyst price targets for the company range from $150 to $220.
Canaccord Genuity kept its Buy rating on Neurocrine Biosciences and increased its price target to $220 from $210, suggesting a 51.4% upside from the Nov 2 close of $145.35. Recent analyst price targets for the company range from $150 to $215.
Neurocrine Biosciences' average stock price target increased to $208.59 from $207.37, with a range of $150 to $253, implying 44% upside from Nov. 2 close. 31 analysts maintain a 'Buy' consensus.
Piper Sandler reaffirmed its Overweight rating on Neurocrine Biosciences and raised its price target to $215 from $210, suggesting a 47.9% upside from the Nov 2 close of $145.35. Recent analyst price targets for the company range from $150 to $207.
Neurocrine reported Q3 2026 revenue of $1.123B, up 41% YoY, driven by INGREZZA ($801M) and CRENESSITY ($211M) sales. GAAP net income was $207M, down from $210M YoY. Non-GAAP EPS rose to $3.29. The company raised INGREZZA's full-year guidance to $2.875B-$2.925B. It also announced new clinical studies and an R&D Day on December 15, 2026.
